Candriam S.C.A. Summit Therapeutics Inc. Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
A detailed history of Candriam S.C.A. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 850,403 shares of SMMT stock, worth $16.1 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
850,403Holding current value
$16.1 Million% of portfolio
0.11%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
191Shares Held
75.8MCall Options Held
1.33MPut Options Held
2.39M-
Baker Bros. Advisors LP New York, NY24.4MShares$463 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$208 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$150 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$103 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$65.8 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.82B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...